Kineta Adds $2.8M Grant

Xconomy Seattle — 

Seattle-based Kineta, the developer of drugs for immune disorders, said it has received a $2.8 million grant from the National Institutes of Health. The grant will support Kineta’s work on a new class of antiviral drugs that trigger the innate immune system to fight various viruses like hepatitis C, influenza, and West Nile. The company said it expects to pick a lead drug candidate in 2012.